Actuate Therapeutics Revenue and Competitors

Dallas, TX USA

Location

$45.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Actuate Therapeutics's estimated annual revenue is currently $904.5k per year.(i)
  • Actuate Therapeutics's estimated revenue per employee is $100,500
  • Actuate Therapeutics's total funding is $45.7M.

Employee Data

  • Actuate Therapeutics has 9 Employees.(i)
  • Actuate Therapeutics grew their employee count by 29% last year.

Actuate Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
2
President & CEOReveal Email/Phone
3
Chief Financial OfficerReveal Email/Phone
4
VP, Operations and Quality AssuranceReveal Email/Phone
5
VP, Chemistry, Manufacturing, & ControlsReveal Email/Phone
6
Sr. Director, OperationsReveal Email/Phone
7
Senior Director, PharmacovigilanceReveal Email/Phone
8
Senior Director, OperationsReveal Email/Phone
9
Director Clinical OperationsReveal Email/Phone
10
Senior Director, Clinical ScienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.4M16120%N/AN/A
#2
$16.3M817%N/AN/A
#3
$18.7M9316%N/AN/A
#4
$62.5M0N/AN/AN/A
#5
$12.3M617%N/AN/A
#6
$3.2MN/A$22.2MN/A
#7
$184.1M91638%$50MN/A
#8
$27.7M1388%N/AN/A
#9
$112.4M5598%N/AN/A
#10
$12.5M6211%N/AN/A
Add Company

What Is Actuate Therapeutics?

Actuate Therapeutics, Inc. is a pharmaceuticals company based out of 1401 FOCH ST, Fort Worth, Texas, United States.

keywords:N/A

$45.7M

Total Funding

9

Number of Employees

$904.5k

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Actuate Therapeutics News

2022-04-19 - Pancreatic And Bile Duct Cancer Drugs Market Size And ...

... AbGenomics International Inc, Ability Pharmaceuticals SL, Aclaris Therapeutics Inc, Actuate Therapeutics Inc, Aduro BioTech Inc.

2022-03-30 - Actuate Therapeutics Announces Poster Presentations at the ...

CHICAGO and FORT WORTH, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical...

2021-10-28 - Actuate Therapeutics Announces Primary Endpoint Met In Phase 2 Study In Pancreatic Cancer

CHICAGO and FORT WORTH, Texas (PRWEB) October 28, 2021 Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met its primary endpoint for ...

2021-08-05 - Actuate Therapeutics Announces FDA Fast Track Designation for 9-ING-41 for Treatment of Pancreatic Cancer

CHICAGO, and FORT WORTH, Texas (PRWEB) August 05, 2021 Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic can ...

2019-11-13 - Actuate Therapeutics Closes $6.5M Series B-3 Financing Round

Actuate Therapeutics, Inc., a Chicago, IL- and Forth Worth, TX-based clinical stage biopharmaceutical company, raised an additional $6.5M in a Series B-3 financing round. This Series B-3, which brought total funding for Actuate’s Series B round to over $28.2M, was led by Bios Partners with part ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M90%N/A
#2
$0.7M913%N/A
#3
$1.3M90%N/A
#4
$0.7M950%N/A
#5
$3.5M9-10%N/A